Latest Breaking News On - Investment in biotechnology companies - Page 4 : vimarsana.com

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹) - Opthea (NASDAQ:OPT)

OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of strong demand from both existing and new domestic and offshore

Opthea Announces "Sozinibercept" as the Nonproprietary Drug Name for OPT-302

Opthea to Present at the 2023 Ophthalmology Innovation Summit

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market

MELBOURNE, Australia, May 17, 2023 -- Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced... | May 17, 2023

Opthea To Present at the JMP Securities Life Sciences Conference

MELBOURNE, Australia, May 08, 2023 -- Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced... | May 8, 2023

Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ

MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today

Opthea (OPT) Reports Publication of Phase 2b Trial Results for OPT-302

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology